Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants

The neutralizing antibody is a potential therapeutic for the ongoing COVID-19 pandemic. As an antiviral agent, numerous mAbs recognize the epitopes that overlap with ACE2-binding sites in the SARS-CoV-2-RBD. Some studies have shown that residual changes on the spike protein can significantly decreas...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fengze, Li, Li, Dou, Yang, Shi, Rui, Duan, Xiaomin, Liu, Hongchuan, Zhang, Jing, Liu, DanDan, Wu, Jing, He, Yang, Lan, Jun, Lu, Bai, Feng, Hui, Yan, Jinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843163/
https://www.ncbi.nlm.nih.gov/pubmed/35060840
http://dx.doi.org/10.1080/22221751.2022.2032374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843163/
https://www.ncbi.nlm.nih.gov/pubmed/35060840
http://dx.doi.org/10.1080/22221751.2022.2032374

Ejemplares similares